**5. Conclusions**

OmeGo, dosed orally, significantly reduced lung and systemic inflammation in an HDM mouse model of induced asthma. Reductions in eosinophils and neutrophils were accompanied by a reduction in total lung collagen, suggesting the potential to moderate airway inflammation and remodelling and help maintain lung function. Human studies are planned in subjects with mild to moderate asthma to assess whether these results can translate into improved asthma control with OmeGo added to standard-of-care treatment.

**Author Contributions:** Conceptualization, B.F. and C.C.; methodology, B.F.; formal analysis, S.L. and E.H.; data curation, B.F. and C.C.; writing—original draft preparation, C.C. and D.S.; writing—review and editing, B.F., C.B., E.H., D.S. and C.C.; visualization, C.C. and D.S.; infographic, S.L.; project administration, B.F.; funding acquisition, B.F. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Hofseth BioCare, Kipervikgata 13, Ålesund, 6003, Norway, funding number R\_21\_224\_003.

**Institutional Review Board Statement:** The animal study protocol was approved by the Institutional Animal Ethics Committee (IAEC proposal number SF\_21\_44\_29).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The raw data, original Project Plan, original final report and a sample of the test items are retained in the Archives of sa-FORD (Sanctuary for Research and Development). Plot number V-10, MIDC Industrial Area, Taloja, Dist: Raigad 410 208, India for a period of 5 years.

**Conflicts of Interest:** D.S. and S.L. declare no conflict of interest. C.C., B.F., C.B. and E.H. are employees of Hofseth BioCare.
